News from Mayo Clinic

April 26, 2016
References
  1. Wein AJ, et al., eds. Diagnosis and staging of prostate cancer. In: Campbell-Walsh Urology. 11th ed. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed Jan. 25, 2016.
  2. Dawson NA. Overview of the treatment of disseminated prostate cancer. http://www.uptodate.com/home. Accessed Jan. 25, 2016.
  3. Niederhuber JE, et al., eds. Prostate cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Jan. 26, 2016.
  4. Lee RJ, et al. Initial systemic therapy for castration sensitive prostate cancer. http://www.uptodate.com/home. Accessed Jan. 25, 2016.
  5. Roach M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014;120:1620.
  6. Smith MR, et al. Side effects of androgen deprivation therapy. http://www.uptodate.com/home. Accessed Jan. 25, 2016.
  7. Dawson NA. Secondary endocrine therapies for castration resistant prostate cancer. http://www.uptodate.com/home. Accessed Jan. 25, 2016.
  8. Steele GS, et al. Radical inguinal orchiectomy for testicular germ cell cancers. http://www.uptodate.com/home. Accessed Jan. 25, 2016.